Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease
- K Fujita1,
- Y Nozaki1,
- K Wada2,
- M Yoneda1,
- H Endo1,
- H Takahashi1,
- T Iwasaki3,
- M Inamori1,
- Y Abe1,
- N Kobayashi1,
- H Kirikoshi1,
- K Kubota1,
- S Saito1,
- Y Nagashima4,
- A Nakajima1
- 1Division of Gastroenterology, Yokohama City University Graduate School of Medicine, Kanazawa-ku, Yokohama, Japan
- 2Department of Pharmacology, Graduate School of Dentistry, Osaka University, Suita, Osaka, Japan
- 3Division of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Kanazawa-ku, Yokohama, Japan
- 4Department of Molecular Pathology, Yokohama City University Graduate School of Medicine, Kanazawa-ku, Yokohama, Japan
- Dr A Nakajima, Division of Gastroenterology, Yokohama City University Graduate School of Medicine, 3-9 Fuku-ura, Kanazawa-ku, Yokohama 236-0004, Japan;
- Revised 30 April 2008
- Accepted 14 May 2008
- Published Online First 2 July 2008
Objective: No effective drugs have been developed to date to prevent or treat non-alcoholic fatty liver disease (NAFLD), although diet modification and exercise to improve obesity have been attempted. Therefore, development of a novel drug/strategy to treat NAFLD is urgently needed. In the present study, a novel concept is proposed for the treatment of NAFLD.
Methods: Fisher 344 male rats were given a choline-deficient, l-amino acid-defined (CDAA) diet or a high-fat high-calorie (HF/HC) diet with or without the antiplatelet agents, aspirin, ticlopidine or cilostazol for 16 weeks. Liver steatosis, inflammation and fibrosis, and the possible mechanisms involved were investigated.
Results: All three antiplatelet drugs, namely aspirin, ticlopidine and cilostazol, significantly attenuated liver steatosis, inflammation and fibrosis in the CDAA diet group. Of the three agents, cilostazol was the most effective, and the drug also suppressed HF/HC diet-induced liver steatosis. Cilostazol appeared to exert its beneficial effect against NAFLD by suppressing mitogen-activated protein kinase activation induced by oxidative stress and platelet-derived growth factor via intercepting signal transduction from Akt to c-Raf.
Conclusion: Antiplatelet agents, especially cilostazol, offer the promise of becoming key agents for the treatment of NAFLD.
Competing interests: None.